Human solute carrier family 35 member F2 (SLC35F2) belongs in drug/metabolite transporter superfamily and is suggested to be a potential oncogene of non-small cell lung cancer. In the present study, we investigated the involvement of SLC25F2 in cell proliferation and gefitinib sensitivity of lung adenocarcinoma using A549 (low gefitinib sensitivity) and PC-9 (high gefitinib sensitivity) cell lines. Gene silencing of SLC35F2 using siRNA suppressed cell proliferation and arrested cell cycle in both A549 and PC-9 cells. The expression of SLC35F2 gene was attenuated in gefitinib-resistant PC-9 cells; however, gene silencing of SLC35F2 did not affect gefitinib sensitivity in both A549 and PC-9 cells. None of thiamine, pyridoxine, folic acid, and nicotinamide had effects on SLC35F2 function and gefitinib sensitivity in both A549 and PC-9 cells. These results indicate that SLC35F2 plays a role in cell proliferation of lung adenocarcinoma but is not involved in its gefitinib sensitivity.
